{"id":"NCT02697734","sponsor":"Novartis Pharmaceuticals","briefTitle":"Efficacy and Safety Evaluation of Osilodrostat in Cushing's Disease","officialTitle":"A Phase III, Multi-center, Randomized, Double-blind, 48 Week Study With an Initial 12 Week Placebo-controlled Period to Evaluate the Safety and Efficacy of Osilodrostat in Patients With Cushing's Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-10-03","primaryCompletion":"2019-06-19","completion":"2020-12-31","firstPosted":"2016-03-03","resultsPosted":"2021-10-19","lastUpdate":"2021-11-01"},"enrollment":73,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Cushing's Disease"],"interventions":[{"type":"DRUG","name":"osilodrostat","otherNames":["LCI699"]},{"type":"DRUG","name":"osilodrostat Placebo","otherNames":[]}],"arms":[{"label":"osilodrostat Group","type":"EXPERIMENTAL"},{"label":"osilodrostat Placebo Group","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study was to confirm efficacy and safety of osilodrostat for the treatment of patients with Cushing's disease who are candidates for medical therapy.","primaryOutcome":{"measure":"Percentage of Randomized Participants With a Complete Response","timeFrame":"at Week 12","effectByArm":[{"arm":"Osilodrostat Group","deltaMin":37,"sd":null},{"arm":"Osilodrostat Placebo Group","deltaMin":2,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":6},"locations":{"siteCount":36,"countries":["United States","Belgium","Brazil","Canada","China","Costa Rica","Greece","Poland","Portugal","Russia","Spain","Switzerland","Thailand","Turkey (TÃ¼rkiye)"]},"refs":{"pmids":["39610378","35325149"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":48},"commonTop":["Decreased appetite","Arthralgia","Fatigue","Nausea","Headache"]}}